mTOR

Mammalian target of Rapamycin

mTOR (mammalian target of Rapamycin) is a protein that in humans is encoded by the mTOR gene. mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. mTOR belongs to the phosphatidylinositol 3-kinase-related kinase protein family. mTOR integrates the input from upstream pathways, including growth factors and amino acids. mTOR also senses cellular nutrient, oxygen, and energy levels. The mTOR pathway is dysregulated in human diseases, such as diabetes, obesity, depression, and certain cancers. Rapamycin inhibits mTOR by associating with its intracellular receptor FKBP12. The FKBP12-rapamycin complex binds directly to the FKBP12-Rapamycin Binding (FRB) domain of mTOR, inhibiting its activity.



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

(+)-Usnic acid

Cat. No.: HY-N0656A

(+)-Usnic acid is isolated from isolated from lichens, binds at the ATP-binding pocket of **mTOR**, and inhibits **mTORC1/2** activity.



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

(32-Carbonyl)-RMC-5552

Cat. No.: HY-134903

(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC_{50}s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2).



Purity: 95.04%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

25(R,S)-Ruscogenin

Cat. No.: HY-N5136

Ruscogenin suppresses HCC metastasis by reducing the expression of MMP-2, MMP-9, uPA, VEGF and HIF-1α via regulating the **PI3K/Akt/mTOR** signaling pathway. And Ruscogenin alleviates LPS-induced pulmonary endothelial cell apoptosis by su.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

3BDO

Cat. No.: HY-U00434

3BDO is a new **mTOR** activator which can also inhibit **autophagy**.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

8-Aminoadenosine

(8-NH2-Ado)

Cat. No.: HY-125927

8-Aminoadenosine (8-NH2-Ado), a RNA-directed nucleoside analogue, reduces cellular ATP levels and inhibits **mRNA synthesis**. 8-Aminoadenosine blocks **Akt/mTOR** signaling and induces **autophagy** and **apoptosis** in a p53-independent manner. 8-Aminoadenosine has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apitolisib

(GDC-0980; GNE 390; RG 7422)

Cat. No.: HY-13246

Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I **PI3** kinase and **mTOR kinase** (**TORC1/2**) inhibitor with **IC_{50}**s of 5 nM/27 nM/7 nM/14 nM for **PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ**, and with a **K_i** of 17 nM for **mTOR**.



Purity: 98.26%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Arnicolide D

Cat. No.: HY-N6843

Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the **caspase** signaling pathway and inhibits the **PI3K/AKT/mTOR** and **STAT3** signaling pathways.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD-8055

Cat. No.: HY-10422

AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive **mTOR** kinase inhibitor with an **IC_{50}** of 0.8 nM. AZD-8055 inhibits both **mTORC1** and **mTORC2**.



Purity: 99.60%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

BGT226

(NVP-BGT226)

Cat. No.: HY-13334A

BGT226 (NVP-BGT226) is a **PI3K** (with **IC_{50}**s of 4 nM, 63 nM and 38 nM for **PI3Kα**, **PI3Kβ** and **PI3Kγ**)/**mTOR** dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

BGT226 maleate

(NVP-BGT226 maleate)

Cat. No.: HY-13334

BGT226 (NVP-BGT226 maleate) is a **PI3K** (with **IC_{50}**s of 4 nM, 63 nM and 38 nM for **PI3Kα**, **PI3Kβ** and **PI3Kγ**) /**mTOR** dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bimiralisib

(PQR309) Cat. No.: HY-12868

Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I **PI3K/mTOR** inhibitor with IC_{50}s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ**, **PI3Kγ** and **mTOR**, respectively. Bimiralisib is an **mTORC1** and **mTORC2** inhibitor.



Purity: 98.74%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Cbz-B3A

Cat. No.: HY-114267

Cbz-B3A is a potent and selective inhibitor of **mTORC1** signaling that appear to bind to ubiquilins 1, 2, and 4, and Cbz-B3A inhibits the phosphorylation of eIF4E-binding protein 1 (4EBP1).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CC-115

Cat. No.: HY-16962

CC-115 is a potent and dual **DNA-PK** and **mTOR** kinase inhibitor with IC_{50}s of 13 nM and 21 nM, respectively. CC-115 blocks both **mTORC1** and **mTORC2** signaling.



Purity: 98.04%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CC-115 hydrochloride

Cat. No.: HY-16962A

CC-115 hydrochloride is a potent and dual **DNA-PK** and **mTOR** kinase inhibitor with IC_{50}s of 13 nM and 21 nM, respectively. CC-115 blocks both **mTORC1** and **mTORC2** signaling.



Purity: 98.23%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CC214-2

Cat. No.: HY-145931

CC214-2 is a potent and dual inhibitor of **mTORC1/mTORC2**. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cyclovirobuxine D

Cat. No.: HY-N0107

Cyclovirobuxine D (CVB-D) is the main active component of the traditional Chinese medicine Buxus microphylla. Cyclovirobuxine D induces **autophagy** and attenuates the phosphorylation of **Akt** and **mTOR**.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

CZ415

Cat. No.: HY-100222

CZ415 is a potent and highly selective **mTOR** inhibitor with a pIC_{50} of 8.07. CZ415 inhibits **mTORC1** and **mTORC2** protein complex.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; ...)

Cat. No.: HY-113038

D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

D-α-Hydroxyglutaric acid disodium

(Disodium (R)-2-hydroxyglutarate) Cat. No.: HY-100542

D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Dactolisib

(BEZ235; NVP-BEZ235) Cat. No.: HY-50673

Dactolisib (BEZ235) is an orally active and dual pan-class I **PI3K** and **mTOR** kinase inhibitor with IC_{50}s of 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for **p110α/p110γ/p110δ/p110β** and **mTOR**, respectively. Dactolisib (BEZ235) inhibits both **mTORC1** and **mTORC2**.



Purity: 99.94%
Clinical Data: Phase 3
Size: 50 mg, 100 mg, 200 mg, 500 mg

Dactolisib Tosylate

(BEZ235 Tosylate; NVP-BEZ 235 Tosylate) Cat. No.: HY-15174

Dactolisib Tosylate (BEZ235 Tosylate) is a dual **PI3K** and **mTOR** kinase inhibitor with IC_{50} values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits **mTORC1** and **mTORC2**.



Purity: 99.88%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg, 500 mg

Desmethyl-VS-5584

(Desmethyl-SB2343) Cat. No.: HY-101776

Desmethyl-VS-5584 is a dimethyl analog of VS-5584 which is an potent and selective **mTOR/PI3K** dual inhibitor with pyrido [2,3-d] pyrimidine structure.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dihydroevocarpine

Cat. No.: HY-N2517

Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the **mTORC1/2** activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Dihydromyricetin

(Ampelopsin; Ampeloptin) Cat. No.: HY-N0112

Dihydromyricetin is a potent inhibitor with an IC_{50} of 48 μM on **dihydropyrimidinase**. Dihydromyricetin can activate autophagy through inhibiting **mTOR** signaling. Dihydromyricetin suppresses the formation of mTOR complexes (**mTORC1/2**).



Purity: 99.79%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

DS-7423

Cat. No.: HY-124036

DS-7423 is a dual **PI3K** and **mTOR** inhibitor, with IC_{50} values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ETP-45658

Cat. No.: HY-110109

ETP-45658 is a potent **PI3K** inhibitor, with IC_{50}s of 22.0 nM, 39.8 nM, 129.0 nM and 717.3 nM for **PI3Kα**, **PI3Kδ**, **PI3Kβ** and **PI3Kγ**, respectively. ETP-45658 also can inhibit **DNA-PK** (IC_{50}=70.6 nM) and **mTOR** (IC_{50}=152.0 nM). ETP-45658 can be used for the research of cancer.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ETP-46464

Cat. No.: HY-15521

ETP-46464 is an effective **mTOR** and **ATR** inhibitor with IC_{50}s of 0.6 and 14 nM, respectively.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Everolimus

(RAD001; SDZ-RAD) Cat. No.: HY-10218

Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active **mTOR1** inhibitor. Everolimus binds to **FKBP-12** to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell **apoptosis** and **autophagy**.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Everolimus-d4

(RAD001-d4; SDZ-RAD-d4) Cat. No.: HY-10218S

Everolimus-d4 (RAD001-d4) is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active **mTOR1** inhibitor. Everolimus binds to **FKBP-12** to generate an immunosuppressive complex.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

FT-1518

Cat. No.: HY-107363

FT-1518 is a new generation selective, potent and oral bioavailable **mTORC1** and **mTORC2** inhibitor, and exhibits antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GDC-0349

Cat. No.: HY-15248

GDC-0349 is a potent and selective ATP-competitive **mTOR** inhibitor with a K_i of 3.8 nM. GDC-0349 inhibits of both **mTORC1** and **mTORC2** complexes.



Purity: 98.42%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Gedatolisib

(PKI-587; PF-05212384)

Cat. No.: HY-10681

Gedatolisib (PKI-587) is a highly potent dual inhibitor of **PI3Kα**, **PI3Kγ**, and **mTOR** with IC_{50}s of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Gedatolisib is equally effective in both complexes of mTOR, **mTORC1** and **mTORC2**.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

GNE-317

Cat. No.: HY-12763

GNE-317 is a **PI3K/mTOR** inhibitor, is able to cross the blood-brain barrier (BBB).



Purity: 99.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GNE-477

Cat. No.: HY-11042

GNE-477 is a potent and efficacious dual **PI3K** (IC_{50}=4 nM)/**mTOR**(K_i=21 nM) inhibitor.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

GNE-490

Cat. No.: HY-10812

GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-**PI3K** inhibitor with IC_{50}s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC_{50}=750 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GNE-493

Cat. No.: HY-10811

GNE-493 is a potent, selective, and orally available dual **pan-PI3-kinase/mTOR** inhibitor with IC_{50}s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.



Purity: 98.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

GSK1059615

Cat. No.: HY-12036

GSK1059615 is a dual inhibitor of **PI3Kα/β/δ/γ** (reversible) and **mTOR** with IC_{50} of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.



Purity: ≥99.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HDACs/mTOR Inhibitor 1

Cat. No.: HY-114414

HDACs/mTOR Inhibitor 1 is a dual **Histone Deacetylases (HDACs)** and **mammalian target of Rapamycin (mTOR)** target inhibitor for treating hematologic malignancies, with IC_{50}**s** of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hederacolchiside A1

Cat. No.: HY-N6950

Hederacolchiside A1, isolated from Pulsatilla chinensis, suppresses proliferation of tumor cells by inducing apoptosis through modulating **PI3K/Akt/mTOR** signaling pathway.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

hSMG-1 inhibitor 11e

Cat. No.: HY-124760

hSMG-1 inhibitor 11e is a potent and selective **hSMG-1 kinase** inhibitor with an IC_{50} of <0.05 nM. hSMG-1 inhibitor 11e shows >900-fold selectivity over mTOR (IC_{50} of 45 nM), PI3Kα/γ (IC_{50}s of 61 nM and 92 nM) and CDK1/CDK2 (IC_{50}s of 32 μM and 7.1 μM).



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

hSMG-1 inhibitor 11j

Cat. No.: HY-124719

hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of **hSMG-1**, with an IC_{50} of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over **mTOR** (IC_{50}=50 nM), **PI3Kα/γ** (IC_{50}=92/60 nM) and **CDK1/CDK2** (IC_{50}=32/7.1 μM).



Purity: 99.81%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

JR-AB2-011

Cat. No.: HY-122022

JR-AB2-011 is a selective **mTORC2** inhibitor with an IC_{50} value of 0.36 μM. JR-AB2-011 inhibits mTORC2 activity by blocking Rictor-mTOR association (K_i: 0.19 μM). JR-AB2-011 has anti-glioblastoma multiforme (GBM) properties.



Purity: 98.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KU-0060648

Cat. No.: HY-13431

KU-0060648 is a dual inhibitor of **PI3K** and **DNA-PK** with IC_{50}s of 4 nM, 0.5 nM, 0.1 nM, 0.594 nM and 8.6 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and DNA-PK, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 5 mg

KU-0063794

Cat. No.: HY-50710

KU-0063794 is a potent and specific **mTOR** inhibitor, inhibiting both the **mTORC1** and **mTORC2** complexes with IC_{50}s of 10 nM.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

L-Leucine

Cat. No.: HY-N0486

L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: ≥98.0%
Clinical Data: Launched
Size: 100 mg

L-Leucine-1-13C,15N

Cat. No.: HY-N0486S7

L-Leucine-1-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Leucine-13C

Cat. No.: HY-N0486S1

L-Leucine-13C is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Leucine-13C6,15N

Cat. No.: HY-N0486S8

L-Leucine-13C6,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Leucine-15N

Cat. No.: HY-N0486S3

L-Leucine-15N is the 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

L-Leucine-18O2

Cat. No.: HY-N0486S10

L-Leucine-18O2 is the 18O-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Leucine-2-13C

Cat. No.: HY-N0486S5

L-Leucine-2-13C is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Leucine-2-13C,15N

Cat. No.: HY-N0486S6

L-Leucine-2-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Leucine-d1

Cat. No.: HY-N0486S11

L-Leucine-d1 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Leucine-d10

Cat. No.: HY-N0486S

L-Leucine-d10 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 25 mg, 50 mg

L-Leucine-d2

Cat. No.: HY-N0486S12

L-Leucine-d2 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Leucine-d3

Cat. No.: HY-N0486S9

L-Leucine-d3 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg, 50 mg, 100 mg

L-Leucine-d7

Cat. No.: HY-N0486S4

L-Leucine-d7 is the deuterium labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Leucine-13C6

Cat. No.: HY-N0486S2

Leucine-13C6 is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the **mTOR** signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MCX 28

Cat. No.: HY-139832

MCX 28, a triple **PI3K/mTOR/PIM** inhibitor, displays low nanomolar activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MHY-1685

Cat. No.: HY-141805

MHY-1685, a novel mammalian target of rapamycin **(mTOR)** inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 100 mg

MHY1485

Cat. No.: HY-B0795

MHY1485 is a potent cell-permeable **mTOR** activator that targets the ATP domain of mTOR. MHY1485 inhibits **autophagy** by suppression of fusion between autophagosomes and lysosomes.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

MT 63-78

Cat. No.: HY-W058849

MT 63-78 is a specific and potent direct **AMPK** activator with an EC_{50} of 25 μM. MT 63–78 also induces cell mitotic arrest and **apoptosis**. MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and **mTORC1** pathways. MT 63-78 has antitumor effects.



Purity: 98.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MTI-31

Cat. No.: HY-126077

MTI-31 is a potent, orally active and highly selective inhibitor of **mTORC1** and **mTORC2**. MTI-31 is selective for **mTOR** (K_d: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

mTOR inhibitor-1

Cat. No.: HY-112914

mTOR inhibitor-1 is a novel **mTOR pathway** inhibitor which can suppress cells proliferation and inducing autophagy.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

mTOR inhibitor-2

Cat. No.: HY-111370

mTOR inhibitor-2 is a highlt potent, selective and oral **mTOR** inhibitor with an IC_{50} of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

mTOR inhibitor-3

Cat. No.: HY-18353

mTOR inhibitor-3 is a remarkably selective **mTOR** inhibitor with a K_i of 1.5 nM. mTOR inhibitor-3 suppresses **mTORC1** and **mTORC2** in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

mTOR inhibitor-8

Cat. No.: HY-131344

mTOR inhibitor-8 is an **mTOR** inhibitor and **autophagy** inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

mTOR/HDAC-IN-1

Cat. No.: HY-141701

mTOR/HDAC-IN-1 (Compound 50) is a selective **mTOR** and **HDAC** dual inhibitor with IC_{50} values of 0.49 and 0.91 nM against mTOR and HDAC1, respectively. mTOR/HDAC-IN-1 can be studied as an **anti-cancer** agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

mTOR/HDAC6-IN-1

Cat. No.: HY-144449

mTOR/HDAC6-IN-IN-1 is a potent **mTOR** and **HDAC6** dual inhibitor (IC_{50}s of 133.7 nM and 56 nM for mTOR and HDAC6, respectively). mTOR/HDAC6-IN-1 can induce significant **autophagy**, **apoptosis** and suppress migration. mTOR/HDAC6-IN-1 has potential to research Triple-negative breast cancer (TNBC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC781406

Cat. No.: HY-100470

NSC781406 is a highly potent **PI3K** and **mTOR** inhibitor with an IC_{50} of 2 nM for PI3Kα.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

NV-5138

Cat. No.: HY-114384

NV-5138, a leucine analog, is the first selective and orally active brain **mTORC1** activator, binding to Sestrin2. NV-5138 is used for antidepressant studies.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NV-5138 hydrochloride

Cat. No.: HY-114384B

NV-5138 hydrochloride, a leucine analog, is the first selective and orally active brain **mTORC1** activator, binding to Sestrin2. NV-5138 hydrochloride is used for antidepressant studies.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Omipalisib

(GSK2126458; GSK458)

Cat. No.: HY-10297

Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of **PI3K** with K_is of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity.



Purity: 99.93%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Onatasertib

(CC-223; ATG-008)

Cat. No.: HY-16956

Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of **mTOR** kinase, with an IC_{50} value for mTOR kinase of 16 nM. Onatasertib inhibits both **mTORC1** and **mTORC2**.



Purity: 95.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

OSI-027

(ASP7486)

Cat. No.: HY-10423

OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive **mTOR** kinase activity inhibitor with an IC_{50} of 4 nM. OSI-027 targets both **mTORC1** and **mTORC2** with IC_{50}s of 22 nM and 65 nM, respectively.



Purity: 99.40%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

OXA-01

Cat. No.: HY-111065

OXA-01 is a potent **mTORC1** and **mTORC2** inhibitor, with IC_{50} values of 29 nM and 7 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Palomid 529

(P529)

Cat. No.: HY-14581

Palomid 529 is a potent inhibitor of **mTORC1** and **mTORC2** complexes.



Purity: 99.47%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-04691502

Cat. No.: HY-15177

PF-04691502 is a potent and selective inhibitor of **PI3K** and **mTOR**. PF-04691502 binds to human PI3Kα, β, δ, γ and mTOR with K_is of 1.8, 2.1, 1.6, 1.9 and 16 nM, respectively.



Purity: 99.64%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-04979064

Cat. No.: HY-100398

PF-04979064 is a potent and selective **PI3K/mTOR** dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

PI-103

Cat. No.: HY-10115

PI-103 is a potent **PI3K** and **mTOR** inhibitor with IC_{50}s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 also inhibits **DNA-PK** with an **IC50** of 2 nM. PI-103 induces **autophagy**.



Purity: 98.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI-103 Hydrochloride

Cat. No.: HY-10115A

PI-103 Hydrochloride is a dual **PI3K** and **mTOR** inhibitor with IC_{50}s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 Hydrochloride also inhibits **DNA-PK** with an **IC50** of 2 nM. PI-103 Hydrochloride induces **autophagy**.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI-103-d8

Cat. No.: HY-10115S

PI-103-d8 is the deuterium labeled PI-103. PI-103 is a potent **PI3K** and **mTOR** inhibitor with IC_{50}s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for **p110α**, **p110β**, **p110δ**, **p110γ**, **mTORC1**, and **mTORC2**. PI-103 also inhibits **DNA-PK** with an **IC50** of 2 nM. PI-103 induces **autophagy**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K-IN-22

Cat. No.: HY-10620

PI3K-IN-22 is a **PI3Kα/mTOR** dual kinase inhibitor. PI3K-IN-22 has IC_{50}s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/Akt/mTOR-IN-2

Cat. No.: HY-146751

PI3K/Akt/mTOR-IN-2 is a **PI3K/AKT/mTOR** pathway inhibitor. PI3K/Akt/mTOR-IN-2 possess anti-cancer effects and selectivity against MDA-MB-231 cells with IC_{50} value of 2.29 μM. PI3K/Akt/mTOR-IN-2 can induce cancer cell cycle arrest and **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/mTOR Inhibitor-1

Cat. No.: HY-112602

PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual **PI3K/mTOR** inhibitor with IC_{50}s of 20/376/204/46 nM and 186 nM for **PI3Kα/PI3Kβ/PI3Kγ/PI3Kδ** and **mTOR**, respectively. Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/mTOR Inhibitor-2

Cat. No.: HY-111508

PI3K/mTOR Inhibitor-2 is a potent dual pan-**PI3K/mTOR** inhibitor with IC_{50}s of 3.4/34/16/1 nM for **PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ** and 4.7 nM for **mTOR**. Antitumor activity.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PI3K/mTOR Inhibitor-3

Cat. No.: HY-141476

PI3K/mTOR Inhibitor-3 (compound 12), an imidazoline, is a potent **PI3K** and **mTOR** dual inhibitor. PI3K/mTOR Inhibitor-3 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3K/mTOR Inhibitor-5

Cat. No.: HY-146016

PI3K/mTOR Inhibitor-5 (compound 19a) is a potent and dual **PI3K** and **mTOR** inhibitor, with IC_{50} values of 86.9 nM and 14.6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Ka-IN-5

Cat. No.: HY-144295

PI3Ka-IN-5 (compound 6 ab) is a potent **PI3Kα/mTOR** inhibitor, with an IC_{50} of 0.7 nM and 3.3 nM, respectively. PI3Ka-IN-5 can be used for the research of colorectal cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kα-IN-5

Cat. No.: HY-144829

PI3Kα-IN-5 (Compound 6ab) is a potent **PI3Kα** inhibitor with an IC_{50} of 0.7 nM. PI3Kα-IN-5 shows antitumor activity with good metabolic stabilities and safety profiles.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PI3Kα/mTOR-IN-1

Cat. No.: HY-U00326

PI3Kα/mTOR-IN-1 is a potent PI3Kα/mTOR dual inhibitor, with an **IC_{50}** of 7 nM for PI3Kα in a cell assay, and **K_i**s of 10.6 nM and 12.5 nM for mTOR and PI3Kα in a cell free assay , respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PKI-179

Cat. No.: HY-11080

PKI-179 is a potent and orally active dual **PI3K/mTOR** inhibitor, with **IC_{50}**s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for **PI3K-α**, **PI3K-β**, **PI3K-γ**, **PI3K-δ** and **mTOR**, respectively. PKI-179 also exhibits activity over **E545K** and **H1047R**, with **IC_{50}**s of 14 nM and 11 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PKI-179 hydrochloride

Cat. No.: HY-11080A

PKI-179 hydrochloride is a potent and orally active dual **PI3K/mTOR** inhibitor, with **IC_{50}**s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for **PI3K-α**, **PI3K-β**, **PI3K-γ**, **PI3K-δ** and **mTOR**, respectively.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PKI-402

Cat. No.: HY-10683

PKI-402 is a selective, reversible, ATP-competitive inhibitor of **PI3K**, including PI3K-α mutants, and **mTOR** (**IC_{50}**=2, 3, 7,14 and 16 nM for PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ).



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Polyphyllin I

Cat. No.: HY-N0047

Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the **JNK** signaling pathway and is an inhibitor of **PDK1/Akt/mTOR** signaling. Polyphyllin I induces **autophagy**, G2/M phase arrest and **apoptosis**.



Purity: 99.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Pomiferin

(NSC 5113)

Cat. No.: HY-N4315

Pomiferin (NSC 5113) acts as an potential inhibitor of **HDAC**, with an **IC_{50}** of 1.05 μM, and also potently inhibits **mTOR** (**IC_{50}**, 6.2 μM).



Purity: 97.36%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PP121

Cat. No.: HY-10372

PP121 is a multi-targeted kinase inhibitor with **IC_{50}**s of 10, 60, 12, 14, 2 nM for **mTOR**, **DNK-PK**, **VEGFR2**, **Src**, **PDGFR**, respectively.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

PP30

Cat. No.: HY-15269

PP30, a TORKinib, is a potent, selective, and ATP-competitive inhibitor of **mTOR** with an **IC_{50}** of 80 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PQR530

Cat. No.: HY-107365

PQR530 is a potent, ATP-competitive, orally bioavailable and brain-penetrant dual pan-**PI3K/mTORC1/2** inhibitor, with a subnanomolar **K_d** toward PI3Kα and mTOR (0.84 and 0.33 nM, respectively). Antitumor activity.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PQR620

Cat. No.: HY-100026

PQR620 is an orally bioavailable and selective brain penetrant inhibitor of **mTORC1/2**.



Purity: 97.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PQR626

Cat. No.: HY-136660

PQR626, a rapamycin derivative, is a potent, selective, orally active, and brain-penetrant **mTOR** inhibitor, with an IC_{50} and K_i of 5 nM and 3.6 nM, respectively. PQR626 can be can be used for the research of neurological disorders.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

QL-IX-55

Cat. No.: HY-15281

QL-IX-55 is a selective ATP-competitive inhibitor of **mTORC1/2** with IC_{50}s of 50/50/10-50 nM for Human mTORC1/Yeast mTORC1/Yeast mTORC2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RapaLink-1

Cat. No.: HY-111373

RapaLink-1, the third-generation bivalent **mTOR** inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker.



Purity: 97.93%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Rapamycin

(Sirolimus; AY-22989)

Cat. No.: HY-10219

Rapamycin (Sirolimus; AY 22989) is a potent and specific **mTOR** inhibitor with an IC_{50} of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of **mTORC1**. Rapamycin is an **autophagy** activator, an immunosuppressant.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Rapamycin-d3

(Sirolimus-d3; AY-22989-d3)

Cat. No.: HY-10219S

Rapamycin-d3 (Sirolimus-d3) is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an $IC_{50}$of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1.



Purity: 95.30%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Rheb inhibitor NR1

Cat. No.: HY-124798

Rheb inhibitor NR1 is a **Rheb** inhibitor with an IC_{50} of 2.1μM in the Rheb-IVK assay. Rheb inhibitor NR1 also is a selective **mTORC1** inhibitor. NR1 inhibits the phosphorylation of ^{T389}pS6K1 and increases the phosphorylation of ^{S473}pAKT in a dose-dependent manner.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg

Ridaforolimus

(MK-8669; Deforolimus; AP23573)

Cat. No.: HY-50908

Ridaforolimus (MK-8669) is a potent and selective **mTOR** inhibitor; inhibits ribosomal protein S6 phosphorylation with an IC_{50} of 0.2 nM in HT-1080 cells.



Purity: 97.83%
Clinical Data: Phase 3
Size: 10 mg, 50 mg

RMC-4529

Cat. No.: HY-115869

RMC-4529 has an IC_{50} value of 1.0 nM against p-4E-BP1-(T37/46) in **mTOR** kinase cellular assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RMC-4627

Cat. No.: HY-143510

RMC-4627 is a selective **mTORC1** inhibitor that activates 4EBP1 and inhibits tumor growth.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RMC-5552

Cat. No.: HY-132168

RMC-5552 is a potent and selective inhibitor of **mTORC1**. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC_{50}s of 0.14 nM and 0.48 nM, respectively. RMC-5552 has anti-cancer activity.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

RMC-6272

(RM-006) Cat. No.: HY-134904

RMC-6272 (RM-006) is a bi-steric **mTORC1**-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors.



Purity: 95.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Rotundic acid

Cat. No.: HY-N2217

Rotundic acid, a triterpenoid obtained from I. rotunda, induces DNA damage and cell apoptosis in hepatocellular carcinoma through **AKT/mTOR** and **MAPK** Pathways. Rotundic acid possesses anti-inflammatory and cardio-protective abilities.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

RP-3500

(ATR inhibitor 4) Cat. No.: HY-139609

RP-3500 (ATR inhibitor 4) is an orally active, selective **ATR** kinase inhibitor (ATRi) with an IC_{50} of 1.00 nM in biochemical assays. RP-3500 shows 30-fold selectivity for ATR over mTOR (IC_{50}=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Salidroside

(Rhodioloside) Cat. No.: HY-N0109

Salidroside is a **prolyl endopeptidase** inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating **mTOR** signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Samotolisib

(LY3023414) Cat. No.: HY-12513

Samotolisib (LY3023414) potently and selectively inhibits **class I PI3K** isoforms, **DNA-PK**, and **mTORC1/2** with IC_{50}s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively.



Purity: 99.42%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sapanisertib

(INK-128; MLN0128; TAK-228) Cat. No.: HY-13328

Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent **mTOR1/2** inhibitor with an IC_{50} of 1 nM for mTOR kinase.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Temsirolimus

(CCI-779) Cat. No.: HY-50910

Temsirolimus is an inhibitor of **mTOR** with an IC_{50} of 1.76 μM. Temsirolimus activates **autophagy** and prevents deterioration of cardiac function in animal model.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 100 mg

Temsirolimus-d3

(CCI-779-d3) Cat. No.: HY-50910S

Temsirolimus-d3 (CCI-779-d3) is the deuterium labeled Temsirolimus. Temsirolimus is an inhibitor of **mTOR** with an IC_{50} of 1.76 μM. Temsirolimus activates **autophagy** and prevents deterioration of cardiac function in animal model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Temsirolimus-d3-1

(CCI-779-d3-1) Cat. No.: HY-50910S2

Temsirolimus-d3-1 (CCI-779-d3-1) is the deuterium labeled Temsirolimus. Temsirolimus is an inhibitor of **mTOR** with an IC_{50} of 1.76 μM. Temsirolimus activates **autophagy** and prevents deterioration of cardiac function in animal model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Temsirolimus-d7

(CCI-779-d7) Cat. No.: HY-50910S1

Temsirolimus-d7 (CCI-779-d7) is the deuterium labeled Temsirolimus. Temsirolimus is an inhibitor of **mTOR** with an IC_{50} of 1.76 μM. Temsirolimus activates **autophagy** and prevents deterioration of cardiac function in animal model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TMBIM6 antagonist-1

Cat. No.: HY-137175

TMBIM6 antagonist-1, a potential **TMBIM6** antagonist, prevents TMBIM6 binding to mTORC2, decreases mTORC2 activity, and also regulates TMBIM6-leaky Ca^{2+}.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

TML-6

Cat. No.: HY-137315

TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and **β-amyloid (Aβ)**. TML-6 can upregulate Apo E, suppress **NF-κB** and **mTOR**, and increase the activity of the anti-oxidative **Nrf2** gene.



Purity: 98.34%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Torin 1

Cat. No.: HY-13003

Torin 1 is a potent inhibitor of **mTOR** with an IC_{50} of 3 nM. Torin 1 inhibits both **mTORC1/2** complexes with IC_{50} values between 2 and 10 nM. Torin 1 is an effective inducer of autophagy.



Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Torin 2

Cat. No.: HY-13002

Torin 2 is an **mTOR** inhibitor with EC_{50} of 0.25 nM for inhibiting cellular mTOR activity, and exhibits 800-fold selectivity over PI3K (EC_{50}: 200 nM). Torin 2 also inhibits **DNA-PK** with an IC_{50} of 0.5 nM in the cell free assay. Torin 2 can suppress both **mTORC1** and **mTORC2**.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Torkinib

(PP 242)

Cat. No.: HY-10474

Torkinib (PP 242) is a selective and ATP-competitive **mTOR** inhibitor with an IC_{50} of 8 nM. PP242 inhibits both **mTORC1** and **mTORC2** with IC_{50}s of 30 nM and 58 nM, respectively.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Vistusertib

(AZD2014)

Cat. No.: HY-15247

Vistusertib (AZD2014) is an ATP competitive **mTOR** inhibitor with an IC_{50} of 2.81 nM. AZD2014 inhibits both **mTORC1** and **mTORC2** complexes.



Purity: 98.21%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Vistusertib-d3

(AZD2014-d3)

Cat. No.: HY-15247S

Vistusertib-d3 (AZD2014-d3) is the deuterium labeled Vistusertib. Vistusertib (AZD2014) is an ATP competitive **mTOR** inhibitor with an IC_{50} of 2.81 nM. AZD2014 inhibits both **mTORC1** and **mTORC2** complexes.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Voxtalisib

(XL765; SAR245409)

Cat. No.: HY-15900

Voxtalisib (XL765) is a potent **PI3K** inhibitor, which has a similar activity toward class I PI3K (IC_{50}s=39, 113, 9 and 43nM for **p110α**, **p110β**, **p110γ** and **p110δ**, respectively), also inhibits DNA-PK (IC_{50}=150nM) and mTOR (IC_{50}=157nM).



Purity: 99.46%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VS-5584

(SB2343)

Cat. No.: HY-16585

VS-5584 is a **pan-PI3K/mTOR** kinase inhibitor with IC_{50}s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks **mTORC2** as well as **mTORC1**.



Purity: 98.15%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WAY-600

Cat. No.: HY-15272

WAY-600 is a potent, ATP-competitive, and selective **mTOR** inhibitor with an IC_{50} of 9 nM for recombinant mTOR enzyme. WAY-600 blocks mTOR complex 1/2 (**mTORC1/2**) assemble and activation.



Purity: 95.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

WYE-132

(WYE-125132)

Cat. No.: HY-10044

WYE-132 (WYE-125132) is a highly potent, ATP-competitive, and specific **mTOR** kinase inhibitor (IC_{50}: 0.19±0.07 nM; >5,000-fold selective versus PI3Ks). WYE-132 (WYE-125132) inhibits **mTORC1** and **mTORC2**.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

WYE-354

Cat. No.: HY-12034

WYE-354 is an ATP-competitive **mTOR** inhibitor with an IC_{50} of 5 nM. WYE-354 also inhibits **PI3Kα** and **PI3Kγ** with IC_{50}s of 1.89 μM and 7.37 μM, respectively. WYE-354 inhibits both **mTORC1** and **mTORC2**. WYE-354 induces autophagy activation in vitro.



Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

WYE-687

Cat. No.: HY-15271

WYE-687 is an ATP-competitive **mTOR** inhibitor with an IC_{50} of 7 nM. WYE-687 concurrently inhibits activation of **mTORC1** and **mTORC2**. WYE-687 also inhibits **PI3Kα** and **PI3Kγ** with IC_{50}s of 81 nM and 3.11 μM, respectively.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WYE-687 dihydrochloride

Cat. No.: HY-15271A

WYE-687 dihydrochloride is an ATP-competitive **mTOR** inhibitor with an IC_{50} of 7 nM. WYE-687 dihydrochloride concurrently inhibits activation of **mTORC1** and **mTORC2**. WYE-687 also inhibits **PI3Kα** and **PI3Kγ** with IC_{50}s of 81 nM and 3.11 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg

XL388

Cat. No.: HY-13806

XL388 is a highly potent and ATP-competitive **mTOR** inhibitor with an IC_{50} of 9.9 nM. XL388 simultaneously inhibits both **mTORC1** and **mTORC2**.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg